MBRX vs. VCNX, PMN, ACXP, CUE, XLO, AADI, IMRX, VYNE, EQ, and LPCN
Should you be buying Moleculin Biotech stock or one of its competitors? The main competitors of Moleculin Biotech include Vaccinex (VCNX), ProMIS Neurosciences (PMN), Acurx Pharmaceuticals (ACXP), Cue Biopharma (CUE), Xilio Therapeutics (XLO), Aadi Bioscience (AADI), Immuneering (IMRX), VYNE Therapeutics (VYNE), Equillium (EQ), and Lipocine (LPCN). These companies are all part of the "pharmaceutical preparations" industry.
Vaccinex (NASDAQ:VCNX) and Moleculin Biotech (NASDAQ:MBRX) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, community ranking, media sentiment, analyst recommendations, risk, dividends and valuation.
50.1% of Vaccinex shares are owned by institutional investors. Comparatively, 15.5% of Moleculin Biotech shares are owned by institutional investors. 51.5% of Vaccinex shares are owned by insiders. Comparatively, 6.7% of Moleculin Biotech shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Moleculin Biotech has a consensus target price of $35.00, suggesting a potential upside of 894.32%. Given Vaccinex's higher probable upside, analysts clearly believe Moleculin Biotech is more favorable than Vaccinex.
Moleculin Biotech received 104 more outperform votes than Vaccinex when rated by MarketBeat users. However, 60.00% of users gave Vaccinex an outperform vote while only 52.42% of users gave Moleculin Biotech an outperform vote.
Moleculin Biotech's return on equity of 0.00% beat Vaccinex's return on equity.
Vaccinex has higher revenue and earnings than Moleculin Biotech.
Vaccinex has a beta of 0.91, indicating that its stock price is 9% less volatile than the S&P 500. Comparatively, Moleculin Biotech has a beta of 1.84, indicating that its stock price is 84% more volatile than the S&P 500.
In the previous week, Vaccinex had 2 more articles in the media than Moleculin Biotech. MarketBeat recorded 5 mentions for Vaccinex and 3 mentions for Moleculin Biotech. Vaccinex's average media sentiment score of 0.96 beat Moleculin Biotech's score of 0.66 indicating that Moleculin Biotech is being referred to more favorably in the news media.
Summary
Vaccinex beats Moleculin Biotech on 7 of the 13 factors compared between the two stocks.
Get Moleculin Biotech News Delivered to You Automatically
Sign up to receive the latest news and ratings for MBRX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MBRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Moleculin Biotech Competitors List
Related Companies and Tools
